Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial
暂无分享,去创建一个
J. Cayuela | H. Dombret | M. Béné | C. Preudhomme | X. Thomas | C. Récher | N. Ifrah | P. Cornillet‐Lefèbvre | J. Delaunay | N. Vey | N. Boissel | C. Berthon | Aline Renneville | O. Blanchet | E. Delabesse | P. Guardiola | E. Jourdan | E. Raffoux | A. Pigneux | N. Contentin | C. Pautas | B. Lioure | J. Lejeune | Edouard Randriamalala | C. Bulabois | N. Fegueux